Tenpoint Therapeutics
London, Capital Region of Denmark, United Kingdom · Biotechnology, Health Care, Therapeutics
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells
Key facts
- Headquarters
- London, Capital Region of Denmark, United Kingdom
- Employees
- 25
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Private
- Website
- tenpointtherapeutics.com
- Company page
Recent activity at Tenpoint Therapeutics
- : Tenpoint Therapeutics raises $85M in Series B to accelerate commercialization of FDA-approved presbyopia treatment Yuvezzi.
- : Tenpoint Therapeutics Appoints Stephen Lane as Chief Medical Officer
- : Tenpoint Therapeutics Appoints Stephen S. Lane as Chief Medical Officer
- : Tenpoint Therapeutics secures $235 million through Series B financing led by Janus Henderson to accelerate commercialization of YUVEZZI™.
- : Tenpoint Appoints Carol Kearney as Chief Commercial Officer for the Potential U.S. Launch of BRIMOCHOL™ PF
- : Tenpoint Therapeutics, Inc. announces positive topline data from BRIO-II study for BRIMOCHOL™ PF to treat presbyopia.
- : Tenpoint Therapeutics Launches With $70 Million Series A Financing To Reverse Vision Loss Through Engineered Cell-Based Therapeutics And In Vivo Reprogramming
Tenpoint Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Series B | $85.0M |
| Jan 2026 | Series B | $235.0M |
| Jul 2023 | Series A | $70.0M |
Leadership
- Stephen Lane, Chief Medical Officer
- Stephen S. Lane, M.D., Chief Medical Officer
- Melissa Epperly, Chief Financial Officer
- Henric Bjarke, Chief Executive Officer
- Henric Bjarke, Chief Executive Officer
- Carol Kearney, Chief Commercial Officer
- Gabriella Rolli, Chief Technology Officer
Verified email and direct lines for Tenpoint Therapeutics’s decision-makers are on Fundz. See plans
Tenpoint Therapeutics in the news
- FDA Approves Yuvezzi to Treat Presbyopia in Adults - Pharmaceutical Executive (Jan 29, 2026)
- Lupin and Tenpoint Therapeutics Announce Strategic Partnership to Commercialize YUVEZZI™ in the European Union, the United Kingdom, Switzerland, Norway, and Iceland - PR Newswire (Aug 20, 2026)
- Tenpoint Therapeutics Ltd. Announces FDA Approval of YUVEZZI™, the First and Only Combination Eye Drop Approved to Treat Presbyopia - Business Wire (Jan 28, 2026)
- FDA approves Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% for presbyopia - Optometry Times (Jan 29, 2026)
- Tenpoint Therapeutics Announces Positive Topline Data from Phase 3 Pivotal Study, BRIO-II, of BRIMOCHOL PF for the Treatment of Presbyopia - Business Wire (Jan 09, 2025)
- Tenpoint Therapeutics launches with $70 million in funding for cell therapy platform - Ophthalmology Times (Jul 13, 2023)
- Tenpoint Therapeutics Secures $235 Million through Series B Stock Financing and Credit Facility to Accelerate Commercialization of YUVEZZI™ - Business Wire (Jan 28, 2026)
Companies similar to Tenpoint Therapeutics
- Paradigm Biopharmaceuticals · Biotechnology, Health Care, Therapeutics
- Navigator Medicines · Biotechnology, Health Care, Therapeutics
- Anavo Therapeutics · Biotechnology, Health Care, Therapeutics
- Gradalis · Biotechnology, Health Care, Therapeutics
- Aethlon Medical · Biotechnology, Health Care, Therapeutics
About Tenpoint Therapeutics: questions and answers
What does Tenpoint Therapeutics do?
Tenpoint is a biotechnology company committed to advancing engineered cell-based therapies and in vivo reprogramming to restore vision for people with degenerative ocular diseases, bringing together the global experts who are shaping the regenerative ocular medicine revolution and the technologies that are driving it. We are addressing the ultimate cause of vision loss by replacing diseased cells
Where is Tenpoint Therapeutics headquartered?
Tenpoint Therapeutics is headquartered in London, Capital Region of Denmark, United Kingdom.
How many employees does Tenpoint Therapeutics have?
Tenpoint Therapeutics has about 25 employees.
Has Tenpoint Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Tenpoint Therapeutics. The most recent, Series B of $85.0M, was in Sep 2026.
Who leads Tenpoint Therapeutics?
Henric Bjarke is a Chief Executive Officer at Tenpoint Therapeutics.
What is the latest news on Tenpoint Therapeutics?
On Sep 24, 2026, Tenpoint Therapeutics raises $85M in Series B to accelerate commercialization of FDA-approved presbyopia treatment Yuvezzi.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy